The information from these trials should aid in the design of future treatment strategies for leukemia patients at high risk of early relapse. Since VM26 in combination chemotherapy effectively destroyed populations of leukemia cells not susceptible to the cytotoxic activity of conventional agents, its most important future role may be in alternate remission induction treatments or perhaps as an added component of primary treatments.
|Number of pages||4|
|Journal||Cancer Chemotherapy and Pharmacology|
|State||Published - Apr 1982|